Literature DB >> 6491862

Studies on the combination of Glycyrrhizae Radix in Shakuyakukanzo-To.

E Sugishita, S Amagaya, Y Ogihara.   

Abstract

The pharmacological properties of the five samples of glycyrrhizic acid, paeoniflorin, the extracts of Glycyrrhizae Radix, the extracts of Paeoniae Radix and a preparation of Chinese drug Shakuyakukanzo-To were compared by investigating their actions in the carrageenan-induced paw edema, the cotton pellet granuloma formation and acetic acid-induced writhing syndrome tests, using ddY-strain mice. The concentrations of glycyrrhizic acid and paeniflorin, the main components of Glycyrrhizae Radix and Paeoniae Radix respectively, were determined in the preparations by high performance liquid chromatography. Anti-inflammatory activity was observed with the doses of glycyrrhizic acid, 3.0 and 30.0 mg/kg p.o., which are almost equivalent to the quantities contained in the extracts of Glycyrrhizae Radix, 18.0 (normal human dose per day) and 180.0 mg/kg, or in Shakuyakukanzo-To, 32.0 (normal human dose per day) and 320.0 mg/kg, respectively and with the doses of the extracts of Glycyrrhizae Radix, 18.0 and 180.0 mg/kg p.o., but not with the doses of Shakuyakukanzo-To, 32.0 and 320.0 mg/kg p.o., in carrageenan-induced edema and cotton pellet method. Doses of paeoniflorin (2.0, 20.0 and 200.0 mg/kg p.o.) and the extracts of Paeoniae Radix, 21.0 (normal human dose per day) and 210.0 mg/kg p.o., which contain almost equivalent quantities of paeoniflorin, 2.0 and 20.0 mg/kg, respectively, showed significant inhibitory effects in the writhing syndrome test. Furthermore, Shakuyakukanzo-To, 32.0 and 320.0 mg/kg p.o., which contain almost equivalent quantities of paeoniflorin, 2.0 and 20.0 mg/kg, showed strong effects in this test.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491862     DOI: 10.1248/bpb1978.7.427

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

1.  Application of quantitative 1H-NMR method to determination of paeoniflorin in Paeoniae radix.

Authors:  Rie Tanaka; Marina Yamazaki; Keiko Hasada; Akito Nagatsu
Journal:  J Nat Med       Date:  2012-10-19       Impact factor: 2.343

2.  Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

Authors:  Hua-Qing Liu; Wei-Yu Zhang; Xue-Ting Luo; Yang Ye; Xing-Zu Zhu
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

3.  The traditional Japanese formula keishibukuryogan inhibits the production of inflammatory cytokines by dermal endothelial cells.

Authors:  Yoko Yoshihisa; Megumi Furuichi; Mati Ur Rehman; Chieko Ueda; Teruhiko Makino; Tadamichi Shimizu
Journal:  Mediators Inflamm       Date:  2010-12-28       Impact factor: 4.711

4.  Potential mechanisms of an antiadenomyosis chinese herbal formula shaoyao-gancao decoction in primary cell culture model.

Authors:  Yong-Ge Guan; Jin-Bin Liao; Kun-Yin Li; Yu-Cui Li; Yang Song; Jing Ling; Zi-Ren Su
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-10       Impact factor: 2.629

5.  Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitis‑induced acute renal injury.

Authors:  Peng Wang; Weixing Wang; Qiao Shi; Liang Zhao; Fangchao Mei; Chen Li; Teng Zuo; Xiaobo He
Journal:  Mol Med Rep       Date:  2016-05-27       Impact factor: 2.952

6.  Metabolism studies of paeoniflorin in rat liver microsomes by ultra-performance liquid chromatography coupled with hybrid quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS).

Authors:  L J Zhu; S S Sun; Y X Hu; Y F Liu
Journal:  R Soc Open Sci       Date:  2018-10-03       Impact factor: 2.963

7.  Paeoniflorin inhibits pulmonary artery smooth muscle cells proliferation via upregulating A2B adenosine receptor in rat.

Authors:  Guoqing Qian; Jin Cao; Chan Chen; Liangxing Wang; Xiaoying Huang; Cheng Ding; Xueding Cai; Fengying Yin; Jinguo Chu; Guoxiang Li; Jinyan Ye
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.